Floatz logo

Geptanolimab

B-cell Non-Hodgkin's Lymphoma

Genor Biopharma Co., Ltd.monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

317 Active assets in the B-cell Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Geptanolimab is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →